Detection and treatment of of early-stage ovarian cancer
AssigneeGeorgia Tech Research Corporation
InventorsDavid Gaul, Facundo M. Fernandez, John Francis McDonald
Life of this patent
Estimating the term…
Abstract
A method of detecting serous ovarian cancer, particularly early stage serous ovarian cancer is described. The method uses up to sixteen compounds found in the blood serum of a person, and determines that changes of some portion of these sixteen compounds can determine the presence of serous ovarian cancer in a women with up to 100% accuracy, specificity, and sensitivity.
Claims30
A method for detecting serous ovarian cancer comprising:
- measuring in a serum sample the concentration of each of ten or more of serous OC metabolites 1 through 16;
- and
- evaluating the amount of change in the concentrations for at least one of the serous OC metabolites 1 through 16 versus a control sample;
- wherein an increase for metabolites 1 through 8 and a decrease for metabolites 9 through 16 indicates a positive result for serous ovarian cancer.
(canceled)
12-15. (canceled)
17-21. (canceled)
A method for eliminating a patient's risk of late-stage serous ovarian cancer comprising:
- collecting a serum sample during the patient's health examination;
- measuring in the serum sample the concentration of each of ten or more of serous OC metabolites 1 through 16;
- comparing the concentration of the serous OC metabolites 1 through 16 to the concentration of the same metabolites in an unaffected control sample to determine the presence or absence of serous ovarian cancer;
- and
- prescribing a treatment regime for the patient.
25-26. (canceled)
28-29. (canceled)
32-33. (canceled)
A non-invasive method for treating serous ovarian cancer comprising
- identifying the presence of serous ovarian cancer in a patient;
- and
- treating the patient with a cancer chemotherapy and/or radiation without resorting to invasive surgical exploration;
- wherein identifying the presence of serous ovarian cancer comprises:
- obtaining a serum sample from the patient;
- measuring in the serum sample the concentration of serous OC metabolites 1 through 16;
- and
- evaluating the change in the concentrations for the serous OC metabolites 1 through 16 versus a control sample.
35-36. (canceled)
(canceled)
41-53. (canceled)
Dependencies are inferred from the claim text.